Mergers & Acquisitions

The firm has a substantial track-record in representation of purchasers and targets in private and public merger and acquisition transactions, and is widely experienced in private and public mergers includes the involvement and advice in reverse mergers, mergers into publicly traded shells, asset purchases and share acquisitions. Some recent examples are the representation of INX Limited in its merger with Valdy Ltd. The sale of majority equity interest of Pixcell Medical Technologies Ltd to Soulbrain Holdings Co., Ltd.

Further examples of such representation include:
o January 2020 - Representation of Famewave Ltd. and its shareholders in its acquisition by Kitov Pharma Ltd.
o April 2019 - Representation Zemingo Group in the transfer of its application development services business to a wholly owned subsidiary, Zemingo Technologies and then the sale of the control of such subsidiary to Emet Computing Ltd. In parallel Zemingo Group raised US$4,500,000 from JVP ventures for the development of its IOT platform.
o July 2018 - Representation of Anima Biotech in a Research and collaboration agreement with Eli Lilly with a total deal value exceeding $1 billion, for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
o June 2017 - represented Eloxx Pharmaceuticals Ltd. in its Series C financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc.
o November 2017 - Representation of iOptima and its shareholders in the sale of the company to a Chinese life sciences corporation in a transaction with an aggregate deal value of up to approximately $50 million. The complex transaction includes an initial investment of $7 million and a multi-stage acquisition of the company from its shareholders.